First Industry Project With Potential to Reduce Carbon Dioxide Emissions up to 90 Percent for One of the Major Manufacturing Sites in Vienna
Innovative High-Temperature Heat Pump System Made in Austria Will Result in More Sustainable Pharmaceutical Production at Takeda Site
Pioneering Steam-Generating Heat Pump Operates Exclusively With 100 Percent Natural Refrigerants
VIENNA, Austria, January 25, 2023: Takeda (TSE:4502/NYSE:TAK) today announced project AHEAD (Advanced Heat Pump Demonstrator) in partnership with the Federal Ministry for Climate Protection, Environment, Energy, Mobility, Innovation and Technology (BMK); the Climate and Energy Fund; and the AIT Austrian Institute of Technology. AHEAD is a New Energy for Industry (NEFI) project as part of the Austrian Science Technology Innovation (FTI) initiative "Flagship region Energy".
In the AHEAD research project, a natural gas-free steam-generating heat pump will be integrated into industrial operation for the first time, aiming to achieve a carbon dioxide (CO2) reduction of up to 90 percent at one of Takeda's major manufacturing sites in Vienna using only natural refrigerants. This project underpins Austria’s leading role in high-temperature heat pump research and is intended to serve as a practical example for the entire pharmaceutical industry as well as other industries aiming to reduce their CO2 emissions.
The innovation of this project is the steam-generating heat pump, which is operated exclusively with 100 percent natural refrigerants and combined with steam compressors to achieve the highest heat recovery temperatures to date. The AHEAD system can reach temperatures of 200-260°C, exceeding temperature needs of Takeda's steam supply, at 184°C, required for manufacturing.
“At Takeda we believe that collaboration is the only way to effectively accelerate our effort to reduce our common environmental footprint,” said Gunter Baumgartner, Global Head Engineering, Takeda. “It allows us to tap into the best technologies available. We are proud to support this pioneering project which again demonstrates how we turn our commitments into actions.”
“Reaching net zero greenhouse gas emissions in our global operations before 2035 requires bold action and pushing the boundaries of what we think is possible,” says Michael Fisher, Global Head Environmental Sustainability and Compliance, Takeda. “Innovative projects like AHEAD need to be an integral part of our journey to net-zero.”
"Austria is committed to becoming climate-neutral by 2040. This important milestone requires a joint effort and Austria's industry plays a key role. Our collaboration with Takeda is a very good example of how we can bring an innovative concept to life,” said Volker Schaffler, Head of Energy and Environmental Technologies, Federal Ministry for Climate Protection, Environment, Energy, Mobility, Innovation and Technology (BMK), Austria. “When industry, research and administration develop solutions together and create the necessary conditions that are needed to achieve our climate and energy targets everyone will win including our citizens. We see our offers as a central lever for achieving our common climate goals."
Pharmaceutical production is very energy-intensive because it requires cooling capacity and the ability to initiate chemical and biological processes, and to ensure a sterile production environment using heat and steam.
To date, a large part of the process heat demand in pharmaceutical production has been created by mainly using natural gas. The AHEAD project will replace natural gas with an innovative, steam-generating heat pump system from the company Sustainable Process Heat, which is combined with steam compressors to generate steam at 11 bar(a)/184°C. A CO2 reduction of up to 90 percent and complete net-zero CO2 emissions over a period of seven months per year will be achieved at Takeda's major manufacturing site in Vienna. This corresponds to 1,900 tonnes reduction of CO2 per year and brings Takeda one step closer to its goal of achieving net-zero greenhouse gas emissions in its own operations before 2035.
The project team will also develop a concept for the replication of the AHEAD system for other Takeda locations in Austria and worldwide. In addition, the decarbonization potential of this technology is being investigated for other important industrial sectors with high energy consumption, such as the paper, chemical and food industries.
The AIT Center for Energy will develop an optimized operating strategy for the AHEAD system and the heat source (excess heat from the cooling supply), based on a comprehensive system model. A novel approach is being developed for the CO2 reduction potential. Process requirements and expected process changes, learning curves for high-temperature heat pumps based on the experience of the project and statistical data are combined.
The technical foundation of the AHEAD project is a CO2-neutral energy center already in operation at the Takeda location in Vienna using 100 percent natural refrigerants. These refrigerants are highly efficient and do not emit CO2.
By centralizing the cooling of the site, it can also be used simultaneously for heat recovery. The excess heat from the refrigeration system is reused and heated to 65 to 70°C with a heat pump. This system is currently used for the heating water at the site.
Once operational, AHEAD will generate steam using the existing heat from the heating water system through another special heat pump. AHEAD is expected to begin operations at the end of 2024, and the final evaluation of the project for research purposes by the AIT is planned at the end of 2025. The research project is funded by the Climate and Energy Fund.
As a science-driven organization, Takeda remains committed to robust environmental sustainability goals aligned with current climate science. The company continues to be carbon neutral across its value chain (including scopes 1, 2, and currently estimated scope 3 GHG emissions1) since 2020 (for its fiscal year 2019 GHG emissions), delivered by a continued focus on internal energy conservation measures, an increased use of renewable energy and the purchase of high-quality carbon offsets. In 2022, Takeda announced an accelerated goal to achieve net-zero GHG emissions related to operations, including scopes 1 and 2, before 2035 and for its entire value chain, including currently estimated1 scope 3 GHG emissions, before 2040.2
In addition to its decarbonization efforts, Takeda has made natural resource conservation commitments supporting water stewardship, responsible waste management and biodiversity, and is also incorporating environmental sustainability principles into its product development stages to minimize the impact of products and packaging throughout their life cycles.
For more information on Takeda’s priorities in advancing environmental sustainability, please visit: https://www.takeda.com/corporate-responsibility/reporting-on-sustainability/planet/.
In Austria Takeda invests from large environmental projects to smaller environmental initiatives. In addition to the power supply from renewable energies from photovoltaic systems and a comprehensive program for waste reduction, an online monitoring system was established more than ten years ago in order to always optimally support supply systems in terms of energy technology. In addition, new solutions and technologies are continuously being reviewed and implemented. Each investment project is examined for sustainable and climate-friendly opportunities. Employee awareness activities and a dedicated biodiversity group also play a role. Some examples of how sustainability is integrated into the production process of pharmaceuticals are: recovery of process waste heat, electricity from renewable energy sources, reducing the number of refrigeration systems by switching to HFC-free, energy-efficient refrigerants. Takeda received the WorldStar Award from the World Packaging Organization (WPO) in 2022 for sustainable drug packaging used at the production site in Vienna. Takeda and its local logistics partner, launched a pilot project in December 2022 with an e-truck that is used for daily supply for the pharmaceutical production in the Vienna area.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
In Austria, Takeda works along the entire pharmaceutical value chain: research & development, plasma application, production and sales. Takeda is Austria's largest pharmaceutical employer. Every day, more than 4,500 employees of which close to 3,000 are in Vienna contribute to ensuring that medicines from Austria reach patients around the world and have access to innovative medicines. Takeda's development and production sites are located in Vienna, Linz and Orth an der Donau. Takeda's Austrian product portfolio helps patients in areas such as oncology, hemophilia and genetic diseases, gastroenterology and immunology. https://www.takeda.at.
Press photos at: http://www.publichealth.at/portfolio-items/Dampf-ohne-Gas/
+81 (0) 3-3278-2325
U.S. and International Media
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
1 A lack of transparency into, and a difficulty measuring, actual Scope 3 emissions remains an important challenge to overcome as part of these efforts.
2 Takeda defines “net-zero” in accordance with the Science Based Targets initiative Corporate Net-Zero Standard and follows the GHG Protocol for carbon neutrality. Additional information on our sustainability programs is available at https://www.takeda.com/corporate-responsibility/reporting-on-sustainability/planet/